NCT04435665View on ClinicalTrials.gov

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 14, 2021

Conditions
Neurofibromatosis 1Cutaneous Neurofibroma
Interventions
DRUG

NFX-179 Gel

gel for topical administration

DRUG

Vehicle Gel

vehicle gel for topical administration

Trial Locations (6)

14623

Skin Search of Rochester, Inc., Rochester

24501

The Education & Research Foundation, Inc., Lynchburg

55112

Minnesota Clinical Study Center, New Brighton

75390

University of Texas Southwestern Medical Center, Dallas

78758

DermResearch, Austin

94538

Center for Dermatology Clinical Research, Inc., Fremont

Sponsors
All Listed Sponsors
lead

NFlection Therapeutics, Inc.

INDUSTRY

NCT04435665 - NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | Biotech Hunter | Biotech Hunter